Eric Venker
President & CEO of ImmunovantDr. Eric Venker, M.D., Pharm.D., has been Chief Executive Officer at Immunovant, Inc. since April 21, 2025 and serves as its Director since February 18, 2020. Dr. Venker served as Chief Operating Officer of Roivant Sciences Ltd. since November 2018 and serves as its President since January 2021. Dr. Venker serves as a Director of Aruvant Sciences, Inc. He serves as Chief Operating Officer of Roivant Sciences, Inc since November 2018 and serves as its President since January 2021. Dr. Venker has been a Director of Dermavant Sciences Ltd. since January 2020. He had been Director at Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies Ltd.) since February 2019 until 2023. Dr. Venker served as Director at Arbutus Biopharma Corporation since February 18, 2020 until May 25, 2022. Dr. Venker first joined Roivant in 2014 and has since served in various roles of increasing responsibility. From October 2017 to October 2018, Dr. Venker served as Chief of Staff to Chief Executive Officer at Roivant Sciences and from 2014 to 2015 as an Analyst at RSI. From 2015 to 2017, Dr. Venker was a physician at New York Presbyterian Hospital/Columbia University Medical Center, where Dr. Venker trained in internal medicine and also served as Chair of the Housestaff Quality Council leading operational initiatives to improve efficiencies. From 2011 to 2015, Dr. Venker was a Clinical Pharmacist at Yale-New Haven Hospital. Dr. Venker was the Founder and Chief Executive Officer of Talking Meds from 2013 to 2017. Dr. Venker received his Pharm. D. from St. Louis College of Pharmacy and his M.D. from Yale University School of Medicine.
Positions
- Company NameRoivant Sciences Ltd.Stock CodeROIVPositionPresident & CEO of Immunovant
- Company NameImmunovant, Inc.Stock CodeIMVTPositionCEO & DirectorColleagues
